IMGN News and Press, ImmunoGen Inc. From 01/05/24

2024-01-05 09:00:00 ET Summary ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has also participated in the aggressive M&A activities ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-01 15:37:15 ET More on AbbVie, Bristol-Myers Squibb Company , etc. Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management Bristol Myers Squibb: Aggress...

NEW YORK, NY / ACCESSWIRE / December 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Rain Oncology Inc. (NASDAQ:...

2023-12-24 09:11:28 ET More on Bristol-Myers Squibb Company , Karuna Therapeutics, etc. Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge Bristol Myers...

2023-12-14 11:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-13 12:05:17 ET Summary Peter Lynch recently pointed out that mega-cap tech stocks are likely overvalued and also shared the segment of the market that he "absolutely" likes right now. We explore why he is bullish on this segment of the market. We also compare two ETFs ...

2023-12-12 10:15:00 ET With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen , (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the pharma is intent on avoiding being left behind by th...

NEW YORK, NY / ACCESSWIRE / December 11, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, In...

Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet Well-Tolerated with Manageable Safety Profile Data Support Continued Development of Trip...